Adocia SA, a clinical-stage biotechnology company headquartered in Lyon, France, operates within the health care sector, focusing on the development of innovative formulations of pre-approved therapeutic proteins and peptides. The company’s primary mission is to address diabetes and other metabolic diseases through its proprietary BioChaperone technological platform. This platform leverages novel polymers, oligomers, and small molecules to enhance the efficacy and safety of therapeutic proteins.

As of the latest available data, Adocia’s stock is listed on the NYSE Euronext Paris, with a market capitalization of approximately €120.83 million. The company’s financial metrics reveal a price-to-earnings ratio of -11.103, reflecting its current non-profitable status. The closing price on March 8, 2026, was €6.24, with a 52-week high of €12.40 on October 14, 2025, and a low of €2.86 on April 6, 2025. This range indicates significant volatility in the stock’s performance over the past year.

Adocia’s clinical product pipeline is diverse, featuring several insulin formulations and combinations aimed at improving diabetes management. Key products include:

  • BioChaperone Lispro U100 and U200: Ultra-rapid formulations of insulin analogs.
  • HinsBet U100: A rapid-acting formulation of human insulin.
  • BioChaperone Combo: A combination of basal insulin glargine and rapid-acting insulin lispro.
  • BioChaperone Pramlintide Insulin: A prandial combination of human insulin with amylin pramlintide.
  • BioChaperone Human Glucagon: An aqueous formulation of human glucagon.

Additionally, Adocia is developing innovative combinations such as:

  • BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide: Combinations of insulin glargine with GLP-1s.
  • BioChaperone Teduglutide: An aqueous formulation of teduglutide, a GLP-2 analog for treating short bowel syndrome.
  • BioChaperone Glucagon GLP-1: A combination of glucagon and a GLP-1 receptor agonist for obesity treatment.

The company has established a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd., which may play a crucial role in its future growth and development.

As of March 6, 2026, Adocia has not reported any new updates. The latest reference data indicates the company’s share count and voting rights, with the last closing price recorded at €6.30. The stock’s current trading level, positioned midway between its 52-week high and low, suggests a moderate market position following a significant upward movement from its lowest point. This positioning reflects the company’s recent trajectory, which remains below its historical peak but well above its lowest recorded value.

Founded in 2005, Adocia continues to focus on advancing its BioChaperone platform to bring innovative therapeutic solutions to market, addressing critical needs in diabetes and metabolic disease management. For more information, interested parties can visit the company’s website at www.adocia.com .